Literature DB >> 20010701

Hospitalization costs associated with hypertension as a secondary diagnosis among insured patients aged 18-64 years.

Guijing Wang1, Zefeng Zhang, Carma Ayala.   

Abstract

BACKGROUND: We estimated the hospitalization costs associated with hypertension as a secondary diagnosis among insured adults aged 18-64 years by using data from 2005 MarketScan Commercial Claims and Encounters (CCAE) inpatient admissions.
METHODS: We analyzed costs for four patient groups (N = 455,944): (i) all selected patients; (ii) patients with the primary diagnosis of ischemic heart disease (IHD); (iii) patients with the primary diagnosis of cerebrovascular disease; and (iv) patients with neither IHD nor cerebrovascular disease as the primary diagnosis. We conducted propensity score matching to control possible bias in cost estimates due to sample selections and estimated the costs of hypertension by using a regression model on the matched populations that controlled for subjects' age, sex, length of hospital stay, Charlson comorbidity index (CCI), region of residence, and urbanization of residence.
RESULTS: For all patients with hypertension as a secondary diagnosis, the estimated average annual hospitalization cost per patient was $21,094, of which $2,734 (13%; P < 0.01) was associated with hypertension. The estimated average costs were $31,106 for patients with a primary diagnosis of IHD, $17,298 for those with a primary diagnosis of cerebrovascular disease, and $18,693 for those without a primary diagnosis of IHD or cerebrovascular disease; hypertension-associated costs for these patients were $3,540 (11.4%; P < 0.01), $1,133 (6.5%; P < 0.01), and $2,254 (12.1%; P < 0.01), respectively.
CONCLUSIONS: Hypertension-associated hospitalization costs are substantial among insured US patients aged 18-64 years with hypertension as a secondary diagnosis and suggest a need for cost-effective programs to prevent, manage, and control hypertension.

Entities:  

Mesh:

Year:  2009        PMID: 20010701     DOI: 10.1038/ajh.2009.241

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  14 in total

1.  Cost of informal caregiving associated with stroke among the elderly in the United States.

Authors:  Heesoo Joo; Diane O Dunet; Jing Fang; Guijing Wang
Journal:  Neurology       Date:  2014-10-10       Impact factor: 9.910

2.  Hospital costs associated with atrial fibrillation for patients with ischemic stroke aged 18-64 years in the United States.

Authors:  Guijing Wang; Heesoo Joo; Xin Tong; Mary G George
Journal:  Stroke       Date:  2015-04-07       Impact factor: 7.914

3.  Hypertension-associated hospitalizations and costs in the United States, 1979-2006.

Authors:  Guijing Wang; Jing Fang; Carma Ayala
Journal:  Blood Press       Date:  2013-07-25       Impact factor: 2.835

4.  Costs of hospitalization for stroke patients aged 18-64 years in the United States.

Authors:  Guijing Wang; Zefeng Zhang; Carma Ayala; Diane O Dunet; Jing Fang; Mary G George
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-08-15       Impact factor: 2.136

5.  Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes.

Authors:  Gregory A Nichols; Edward J Moler
Journal:  Metab Syndr Relat Disord       Date:  2010-12-18       Impact factor: 1.894

6.  Depression and risk of hospitalizations for ambulatory care-sensitive conditions in patients with diabetes.

Authors:  Dimitry S Davydow; Wayne J Katon; Elizabeth H B Lin; Paul Ciechanowski; Evette Ludman; Malia Oliver; Michael Von Korff
Journal:  J Gen Intern Med       Date:  2013-01-17       Impact factor: 5.128

7.  Hypertension-associated expenditures for medication among US adults.

Authors:  Guijing Wang; Lili Yan; Carma Ayala; Mary G George; Jing Fang
Journal:  Am J Hypertens       Date:  2013-05-31       Impact factor: 2.689

8.  The Hospitalization Costs of Diabetes and Hypertension Complications in Zimbabwe: Estimations and Correlations.

Authors:  Mutsa P Mutowo; Paula K Lorgelly; Michael Laxy; Andre M N Renzaho; John C Mangwiro; Alice J Owen
Journal:  J Diabetes Res       Date:  2016-06-15       Impact factor: 4.011

9.  Full coverage for hypertension drugs in rural communities in China.

Authors:  Baorong Yu; Xiaojuan Zhang; Guijing Wang
Journal:  Am J Manag Care       Date:  2013-01-01       Impact factor: 2.229

10.  Economic aspects of hypertension treatment in Poland.

Authors:  Jana Krzysztoszek; Dorota Koligat; Piotr Ratajczak; Wiesław Bryl; Maciej Cymerys; Karolina Hoffmann; Ewelina Wierzejska; Paweł Kleka
Journal:  Arch Med Sci       Date:  2013-01-21       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.